Sugi Predict

Sugi Predict / Compounds / SCHEMBL2091665

SCHEMBL2091665

SCHEMBL2091665

[O]Cc1csc(-c2cc(Cl)cc(Cl)c2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GFER P55789 1/20 0.49
▸ LMNA P02545 4/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.45
▸ TLR7 Q9NYK1 1/20 0.43
▸ KDM4E B2RXH2 5/20 0.40
▸ ALDH1A1 P00352 5/20 0.40
▸ TDP1 Q9NUW8 4/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ MAPT P10636 6/20 0.39
▸ NPC1 O15118 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ RHOC P08134 1/20 0.38
▸ RHOA P61586 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092986 0.86 CYP1A1 (0.51) GFERLMNAKDM4EALDH1A1TDP1
SCHEMBL18015905 0.82 RAB9A (0.49) GFERLMNAL3MBTL1RXFP1TLR7
SCHEMBL2091378 0.82 GFER (0.72) GFERLMNAKDM4EALDH1A1TDP1
SCHEMBL18014780 0.78 GFER (0.45) GFERLMNAL3MBTL1RXFP1TLR7
SCHEMBL2097145 0.74 KDM4E (0.58) LMNAL3MBTL1KDM4EALDH1A1RAB9A
SCHEMBL2090850 0.72 SHMT1 (0.44) GFERLMNAL3MBTL1RXFP1ALDH1A1
SCHEMBL18003355 0.72 SMN1; SMN2 (0.45) GFERLMNAL3MBTL1RXFP1TLR7
SCHEMBL2089431 0.72 LMNA (0.39) GFERLMNAL3MBTL1KDM4EALDH1A1
SCHEMBL10029563 0.71 KDM4E (0.54) LMNAKDM4EALDH1A1MAPTGAA
SCHEMBL2550683 0.69 TLR7 (0.64) LMNAL3MBTL1TLR7KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 — — US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 — — EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 — — US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 — — EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 GFER 700/4885LMNA 4594/4885L3MBTL1 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.